Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | PBK | Q96KB5 | 6/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21476003 | 0.86 | PTGS2 (0.46) | PTGS2ACACBHTR2AHRH1AOC2 | |
| SCHEMBL21484164 | 0.81 | ACACB (0.36) | PTGS2ACACBAOC3HTR2AHRH1 | |
| SCHEMBL11317932 | 0.78 | PTGS2 (0.49) | PTGS2ACACBTDP1ALDH1A1MAPT | |
| SCHEMBL1106467 | 0.69 | KDM4E (0.39) | PTGS2ACACBAOC2ALDH1A1 | |
| SCHEMBL23266882 | 0.68 | PTGS2 (0.44) | PTGS2ACACBAOC2RAB9AALDH1A1 | |
| SCHEMBL26901678 | 0.68 | PDPK1 (0.39) | AOC3HTR2AHRH1TDP1RAB9A | |
| SCHEMBL26007774 | 0.68 | PTGS2 (0.46) | PTGS2TDP1ALDH1A1MAPTHTT | |
| SCHEMBL17014806 | 0.67 | PTGS2 (0.41) | PTGS2ACACBAOC2 | |
| SCHEMBL12890143 | 0.67 | PTGS2 (0.41) | PTGS2ACACBAOC2ALDH1A1MAPT | |
| SCHEMBL589332 | 0.67 | PTGS2 (0.38) | PTGS2ACACBAOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | PTGS2 4366/4885ACACB 4201/4885AOC3 3581/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | PTGS2 4438/4885ACACB 3915/4885AOC3 4293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.